JWJochen Walker

Jochen Walker

*This is an algorithmically generated author record based on publicly available information.

Jochen Walker has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Annette Becker

    Department of General Medicine, Preventive and Rehabilitation Medicine, University of Marburg, Marburg, Germany

    1 shared publication
  • Annika Viniol

    Department of General Medicine, Preventive and Rehabilitation Medicine, University of Marburg, Marburg, Germany

    1 shared publication
  • Frank Andersohn

    Institute of Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin, Berlin, Germany

    1 shared publication
  • Jörg Haasenritter

    Department of General Medicine, Preventive and Rehabilitation Medicine, University of Marburg, Marburg, Germany

    1 shared publication
  • Karl Martin Klein

    Epilepsy Center Frankfurt Rhine-Main, Department of Neurology, University Medical Center and Goethe University Frankfurt, Frankfurt, Germany

    1 shared publication
  • Lennart Hickstein

    Institute for Applied Health Research Berlin, InGef, Berlin, Germany

    1 shared publication

Latest Publications

  • Open Access

    Prescribing practice of pregabalin/gabapentin in pain therapy: an evaluation of German claim data

    by Annika Viniol, Tina Ploner, Lennart Hickstein, Jörg Haasenritter, Karl Martin Klein, Jochen Walker, Norbert Donner-Banzhoff, Annette Becker

    Objectives To analyse the prevalence and incidence of pregabalin and gabapentin (P/G) prescriptions, typical therapeutic uses of P/G with special attention to pain-related diagnoses and discontinuation rates. Design Secondary data analysis. Setting Primary and secondary care in Germany. Participants Four million patients in the years 2009–2015 (anonymous health insurance data). Intervention None. Primary and secondary outcome measures P/G prescribing rates, P/G prescribing rates associated with pain therapy, analysis of pain-related diagnoses leading to new P/G prescriptions and the discontinuation rate of P/G. Results In 2015, 1.6% of insured persons received P/G prescriptions. Among the patients with pain first treated with P/G, as few as 25.7% were diagnosed with a typical neuropathic pain disorder. The remaining 74.3% had either not received a diagnosis of neuropathic pain or showed a neuropathic component that was pathophysiologically conceivable but did not support the prescription of P/G. High discontinuation rates were observed (85%). Among the patients who had discontinued the drug, 61.1% did not receive follow-up prescriptions within 2 years. Conclusion The results show that P/G is widely prescribed in cases of chronic pain irrespective of neuropathic pain diagnoses. The high discontinuation rate indicates a lack of therapeutic benefits and/or the occurrence of adverse effects.


  • Characteristics and external validity of the German Health Risk Institute (HRI) Database

    by Frank Andersohn, Jochen Walker

    Purpose The aim of this study was to describe characteristics and external validity of the German Health Risk Institute (HRI) Database. Methods The HRI Database is an anonymized healthcare database with longitudinal data from approximately six Mio Germans. In addition to demographic information (gender, age, region of residence), data on persistence of insurants over time, hospitalization rates, mortality rates and drug prescription rates were extracted from the HRI database for 2013. Corresponding national reference data were obtained from official sources. Results The proportion of men and women was similar in the HRI Database and Germany, but the database population was slightly younger (mean 40.4 vs 43.7 years). The proportion of insurants living in the eastern part of Germany was lower in the HRI Database (10.1% vs 19.7%). There was good accordance to German reference data with respect to hospitalization rates, overall mortality rate and prescription rates for the 20 most often reimbursed drug classes, with the overall burden of morbidity being slightly lower in the HRI database. From insurants insured on 1 January 2009 (N = 6.2 Mio), a total of 70.6% survived and remained continuously insured with the same statutory health insurance until 31 December 2013. This proportion increased to 77.5% if only insurants ≥40 years were considered. Conclusions There was good overall accordance of the HRI database and the German population in terms of measures of morbidity, mortality and drug usage. Persistence of insurants with the database over time was high, indicating suitability of the data source for longitudinal epidemiological analyses. Copyright © 2015 John Wiley & Sons, Ltd.